Last reviewed · How we verify

Postencephalitic parkinsonism — Treatment Landscape & Competitive Intelligence

Postencephalitic parkinsonism (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Postencephalitic parkinsonism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Parlodel BROMOCRIPTINE Esjay Pharma Ergot Derivative D(2) dopamine receptor 1978-01-01
Sinemet Cr CARBIDOPA Aton Aromatic Amino Acid [EPC] Lysine-specific demethylase 4E 1975-01-01
Inbrija LEVODOPA Merz Aromatic Amino Acid [EPC] Tyrosine-protein kinase Fyn 1970-01-01
Gocovri AMANTADINE Endo Influenza A M2 Protein Inhibitor Sigma non-opioid intracellular receptor 1 1968-01-01
Akineton BIPERIDEN AbbVie Anticholinergic Muscarinic acetylcholine receptor M1 1959-01-01
Cogentin Cogentin University of Southern California 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
GOCOVRI GOCOVRI Oregon Health and Science University Influenza A M2 Protein Inhibitor Sigma non-opioid intracellular receptor 1
Amantadin Amantadin Centre Hospitalier Universitaire de Nice Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor
Bromocriptin Bromocriptin University Hospital, Bonn 5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor
Lodosyn Lodosyn University of Miami Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 4 drugs in Postencephalitic parkinsonism
  2. AbbVie · 1 drug in Postencephalitic parkinsonism
  3. Aton · 1 drug in Postencephalitic parkinsonism
  4. Centre Hospitalier Universitaire de Nice · 1 drug in Postencephalitic parkinsonism
  5. Endo · 1 drug in Postencephalitic parkinsonism
  6. Esjay Pharma · 1 drug in Postencephalitic parkinsonism
  7. Merz · 1 drug in Postencephalitic parkinsonism
  8. Oregon Health and Science University · 1 drug in Postencephalitic parkinsonism
  9. University Hospital, Bonn · 1 drug in Postencephalitic parkinsonism
  10. University of Miami · 1 drug in Postencephalitic parkinsonism
  11. University of Southern California · 1 drug in Postencephalitic parkinsonism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Postencephalitic parkinsonism:

Cite this brief

Drug Landscape (2026). Postencephalitic parkinsonism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postencephalitic-parkinsonism. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing